These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17239287)

  • 1. Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
    Herbst RS
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S23-30. PubMed ID: 17239287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Horn L; Sandler AB
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis Inhibitors in NSCLC.
    Manzo A; Montanino A; Carillio G; Costanzo R; Sandomenico C; Normanno N; Piccirillo MC; Daniele G; Perrone F; Rocco G; Morabito A
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
    Vaklavas C; Lenihan D; Kurzrock R; Tsimberidou AM
    Oncologist; 2010; 15(2):130-41. PubMed ID: 20139170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 8. [Dermatologic side effects induced by new angiogenesis inhibitors].
    Sibaud V; Garrido-Stowhas I; Cottura E; Chevreau C
    Bull Cancer; 2011 Oct; 98(10):1221-9. PubMed ID: 22001771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
    Girardi F; Franceschi E; Brandes AA
    Oncologist; 2010; 15(7):683-94. PubMed ID: 20547589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Angiogenesis and renal cell carcinoma].
    Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lung cancer].
    Fischer B; Buhl R
    Med Klin (Munich); 2008 May; 103(5):311-20. PubMed ID: 18484217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
    Wu S; Keresztes RS
    Cancer Invest; 2011 Aug; 29(7):460-71. PubMed ID: 21740083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects of anticancer agents that target the VEGF pathway.
    Chen HX; Cleck JN
    Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of adverse effects of anti-VEGF therapy for cancer.
    Kamba T; McDonald DM
    Br J Cancer; 2007 Jun; 96(12):1788-95. PubMed ID: 17519900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
    Bose D; Meric-Bernstam F; Hofstetter W; Reardon DA; Flaherty KT; Ellis LM
    Lancet Oncol; 2010 Apr; 11(4):373-82. PubMed ID: 20171141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
    Azad NS; Aragon-Ching JB; Dahut WL; Gutierrez M; Figg WD; Jain L; Steinberg SM; Turner ML; Kohn EC; Kong HH
    Clin Cancer Res; 2009 Feb; 15(4):1411-6. PubMed ID: 19228742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
    Snider KL; Maitland ML
    Target Oncol; 2009 Apr; 4(2):67-76. PubMed ID: 19373440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L
    J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.